Table 2.
The effect of CD13 silencing on the IC50 values and RIs for SGC7901/X cells after treatment with chemotherapeutic drugs for 24 h.
| Drugs | SGC7901 IC50 (ug/ml) |
SGC7901/X+ pTZU6+1 |
SGC7901/X+ pTZU-CD13-shRNA | ||
|---|---|---|---|---|---|
| IC50(ug/ml) | RI | IC50(ug/ml) | RI | ||
| 5-fluorouracil | 22.6±0.1 | 188.1±0.3 | 8.3±0.3 | 75.4±0.3∗∗ | 3.7±0.2∗∗ |
|
| |||||
| Cisplatin | 1.25±0.01 | 20.1±0.2 | 18.8±0.1 | 10.23±0.1∗∗ | 8.13±0.2∗∗ |
|
| |||||
| Oxaliplatin | 0.42±0.02 | 8.51±0.1 | 21.31±0.2 | 4.53±0.1∗∗ | 10.8±0.1∗∗ |
IC50 values and RIs were determined by the CCK-8 method. Data are expressed as means ± SD from three independent experiments. ∗∗P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without pTZU-CD13-shRNA transfection.